Tumor immunotargeting using innovative radionuclides.

Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Cédric Mathieu, François Guérard, Eric Frampas, Thomas Carlier, Nicolas Chouin, Ferid Haddad, Jean-François Chatal, Alain Faivre-Chauvet, Michel Chérel, Jacques Barbet

Journal: International journal of molecular sciences 2015;16(2):3932-54

PMID: 25679452

Free Full Text on MDPI View on PubMed

Abstract

This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.

Address: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Department of Nuclear Medicine, University Hospital, Nantes 44093, France. [email protected].; Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Department of Nuclear Medicine, University Hospital, Nantes 44093, France. [email protected].; Department of Nuclear Medicine, University Hospital, Nantes 44093, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Department of Radiology, University Hospital, Nantes 44093, France. [email protected].; AMAROC, ONIRIS, Nantes 44300, France. [email protected].; Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. [email protected].; Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. [email protected].; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. [email protected].; Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. [email protected].

DOI: 10.3390/ijms16023932

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

MeSH Terms: Antibodies, Monoclonal, Diagnostic Imaging, Humans, Neoplasms, Radioimmunotherapy, Radioisotopes, Radionuclide Imaging